Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Alpelisib by Novartis for Endometrial Cancer: Likelihood of Approval
Alpelisib is under clinical development by Novartis and currently in Phase III for Endometrial Cancer. According to GlobalData, Phase III...
Data Insights
Alpelisib by Novartis for Metastatic Breast Cancer: Likelihood of Approval
Alpelisib is under clinical development by Novartis and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase...